|
|
Other links at Articles > Cardiology |
| 1. |
Disputed Echo Results From MIST I Require Regulatory Attention, Article States
|
|
|
Dr Jonathan Tobis argues that the FDA and the MHRA in the UK should step in to clear up the "mist of confusion" created by the disparate residual-shunt data reported officially and unofficially for MIST I. While the FDA is refusing to comment, the UK agency says it has reviewed the data and found no sign of safety or efficacy problems with the STARflex device. Heartwire
|
| 2. |
TRITON: Consistent Reduction in Stent Thrombosis Seen
|
|
|
A new analysis from the TRITON-TIMI 38 trial shows similar significant reductions in stent thrombosis with prasugrel vs clopidogrel irrespective of stent type and stent-thrombosis definition. The risk of stent thrombosis will therefore be another factor that can be considered when weighing which of these antiplatelet agents to use, TRITON investigators said. Heartwire
|
| 5. |
ARBs Unable to TRANSCEND Placebo in High-Risk Patients
|
|
|
The angiotensin-receptor blocker telmisartan has fared no better than placebo in TRANSCEND in patients at high-risk of cardiovascular disease unable to tolerate ACE inhibitors, seemingly providing more questions than answers. Heartwire
|
|
|
